[Methotrexate treatment in non-cancerous disorders].
Weekly administration of low doses methotrexate (7.5 mg to 25 mg a week) is considered as one of the most important progresses in the management of rheumatoid arthritis. Its efficacy has also been demonstrated for the treatment of other inflammatory processes such as psoriasis arthritis and, more recently, Crohn's disease. We here review the indications, the limits and the side effects of such therapeutic approach in various inflammatory and/or autoimmune diseases.
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D003879:Dermatologic Agents / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy
D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D005493:Folic Acid Antagonists; D007166:Immunosuppressive Agents; D008727:Methotrexate
Traitement par méthotrexate en dehors des affections cancéreuses.